Anzeige
Mehr »
Login
Mittwoch, 08.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
293 Leser
Artikel bewerten:
(1)

Marechale Capital Plc - Placing, Subscription and Issue of Equity

Finanznachrichten News

Marechale Capital Plc - Placing, Subscription and Issue of Equity

PR Newswire

26 January 2021

Marechale Capital plc

("Marechale" or the "Company")

Placing, Subscription and Issue of Equity

Marechale Capital Plc (AIM: MAC) is pleased to announce that it has conditionally raised the sum of £250,000 before expenses via a placing and subscription of 20,000,000 new ordinary shares of 0.8p each in the Company ("New Ordinary Shares") at a price of 1.25p ("Placing Price") per share ("Fundraise").

Marechale is an established corporate finance firm providing strategic, M&A and advisory services primarily to hospitality and renewable energy companies in the UK and Europe. Marechale also finances earlier stage and growth capital companies from its family office, private investor and private equity relationships. The purpose of this strategic fundraising is to put the Company in a better position to take advantage of investment and co-investment opportunities that are presented to Marechale in connection with its activity for corporate clients. The Company sees significant potential for growth within the hospitality and leisure industries and the technology sector as the economy recovers from the current pandemic and the Directors consider that a stronger balance sheet will allow it greater scope to capitalise on and participate in financing opportunities.

The Fundraise has been completed by a number of new and existing investors, including the Company's Chief Executive, Patrick Booth-Clibborn, who has invested £20,000 to subscribe for 1,600,000 New Ordinary Shares at the Placing Price. Following Admission, Patrick Booth-Clibborn will hold a total of 9,844,740 ordinary shares representing 12.7 per cent. of the Company's enlarged issued Share Capital.Chris Akers, who has also participated in the Fundraise, will, on Admission, have an interest in 7,690,000 shares representing 9.9 per cent. of the Company's enlarged issued share capital.

The New Ordinary Shares will rank pari passu with the existing ordinary shares. Application will be made for the new shares to be admitted to trading on AIM with admission expected to take place on, or around, 9 February 2021 ("Admission"). Completion of the Fundraise is conditional on Admission.

Following Admission, the Company's enlarged share capital will comprise 77,681,151 ordinary shares. No shares are held in Treasury. Therefore, the total number of Ordinary Shares with voting rights will be 77,681,151. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The participation in the Fundraise by Patrick Booth-Clibborn is a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. With the exception of Patrick Booth-Clibborn, the directors consider, having consulted with the Company's Nominated Adviser Cairn Financial Advisers LLP, that the terms of the transaction are fair and reasonable insofar as shareholders are concerned.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact:

Marechale Capital plc
Mark Warde-Norbury / Patrick Booth-Clibborn
Tel: +44 (0)20 7628 5582
Cairn Financial Advisers LLP (Nomad)
Jo Turner / Sandy Jamieson / Mark Rogers
Tel: +44 (0)20 7213 0880
Novum Securities Limited (Broker)
Colin Rowbury
Tel: +44 (0)20 7399 9427

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1Details of the person discharging managerial responsibilities/person closely associated
a.NamePatrick Booth-Clibborn
2Reason for notification
a.Position/StatusChief Executive
b.Initial notification/
Amendment
Initial
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.NameMarechale Capital Plc
b.LEI213800WAVVOPS85N2205
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.Description of the financial instrument, type of instrument

Identification Code
Ordinary Shares



ISIN: GB0005401087
b.Nature of the transactionSubscription for ordinary shares
c.Price(s) and volume(s)
Volume(s)Price (p)
  1. 1,600,000
1.25p
d.Aggregated information

- Aggregated Volume
- Price


-1,600,000
-1.25 pence per share
e.Date of the transaction26/1/2021
f.Place of the transactionLondon Stock Exchange, AIM
© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.